The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | R | Respiratory system | |
| 2 | R06 | Antihistamines for systemic use | |
| 3 | R06A | Antihistamines for systemic use | |
| 4 | R06AD | Phenothiazine derivatives | |
| 5 | R06AD01 | Alimemazine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 30 mg |
| PAREN - Parenteral | 30 mg |
| Active Ingredient | Description | |
|---|---|---|
| Alimemazine |
Alimemazine has a central sedative effect, comparable to that of chlorpromazine, but largely devoid of the latter’s antiadrenaline action. It has powerful antihistamine and anti-emetic actions. Alimemazine is used to treat neurosis, depression and anxiety of different origins. It prevents and relieves allergic conditions, which cause pruritus and urticaria by blocking histamine produced by the body during an allergic reaction. Alimemazine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
